DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES

The aim of our review has been to give an appropriate idea of analogies and differences between primitive MDS (p-MDS) and t-MDS throughout an accurate reviewing of English peer-reviewed literature focusing on clinical, cytogenetic, epigenetic, and somatic mutation features of these two groups of di...

Full description

Saved in:
Bibliographic Details
Main Authors: Prof. Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso
Format: Article
Language:English
Published: PAGEPress Publications 2022-04-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Online Access:https://www.mjhid.org/index.php/mjhid/article/view/4986
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850180073448013824
author Prof. Giuseppe Leone
Emiliano Fabiani
Maria Teresa Voso
author_facet Prof. Giuseppe Leone
Emiliano Fabiani
Maria Teresa Voso
author_sort Prof. Giuseppe Leone
collection DOAJ
description The aim of our review has been to give an appropriate idea of analogies and differences between primitive MDS (p-MDS) and t-MDS throughout an accurate reviewing of English peer-reviewed literature focusing on clinical, cytogenetic, epigenetic, and somatic mutation features of these two groups of diseases. Therapy-related MDS (t-MDS) are classified by WHO together with therapy-related acute myeloid leukemia (t-AML) in the same group, named therapy-related myeloid neoplasm. However, in clinical practice, the diagnosis of t-MDS is made with the same criteria as for primitive MDS (p-MDS), and the only difference is a previous non-myeloid neoplasm. The prognosis and the consequent therapy can be established following the same criteria as for p-MDS, and the therapy is generally decided using the same criteria. We stress the possible difference in cytogenetics, mutations, and epigenetics to distinguish the two forms. Actually, there is no marker specific for t-MDS either in cytogenetics, epigenetics, or mutations; however, some alterations are also frequent in t-MDS and, in general, they induce a poorer prognosis. So, the high-risk forms in t-MDS are prevalent. The present literature data suggest classifying the t-MDS as a subgroup of MDS and introducing some parameters to evaluate the probability of previous therapy in inducing MDS. An important issue remains the patient’s fitness, which strongly influences the outcome. Keywords: MDS, t-MDS- Cytogenetics, Mutation, Epigenetics.
format Article
id doaj-art-d1a61c854ebc4eea84801c7adaf7a34c
institution OA Journals
issn 2035-3006
language English
publishDate 2022-04-01
publisher PAGEPress Publications
record_format Article
series Mediterranean Journal of Hematology and Infectious Diseases
spelling doaj-art-d1a61c854ebc4eea84801c7adaf7a34c2025-08-20T02:18:19ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062022-04-0114110.4084/MJHID.2022.030DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCESProf. Giuseppe LeoneEmiliano FabianiMaria Teresa Voso0Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy. The aim of our review has been to give an appropriate idea of analogies and differences between primitive MDS (p-MDS) and t-MDS throughout an accurate reviewing of English peer-reviewed literature focusing on clinical, cytogenetic, epigenetic, and somatic mutation features of these two groups of diseases. Therapy-related MDS (t-MDS) are classified by WHO together with therapy-related acute myeloid leukemia (t-AML) in the same group, named therapy-related myeloid neoplasm. However, in clinical practice, the diagnosis of t-MDS is made with the same criteria as for primitive MDS (p-MDS), and the only difference is a previous non-myeloid neoplasm. The prognosis and the consequent therapy can be established following the same criteria as for p-MDS, and the therapy is generally decided using the same criteria. We stress the possible difference in cytogenetics, mutations, and epigenetics to distinguish the two forms. Actually, there is no marker specific for t-MDS either in cytogenetics, epigenetics, or mutations; however, some alterations are also frequent in t-MDS and, in general, they induce a poorer prognosis. So, the high-risk forms in t-MDS are prevalent. The present literature data suggest classifying the t-MDS as a subgroup of MDS and introducing some parameters to evaluate the probability of previous therapy in inducing MDS. An important issue remains the patient’s fitness, which strongly influences the outcome. Keywords: MDS, t-MDS- Cytogenetics, Mutation, Epigenetics. https://www.mjhid.org/index.php/mjhid/article/view/4986Primitive MDStherapy related MDSMutationsCytogenetics
spellingShingle Prof. Giuseppe Leone
Emiliano Fabiani
Maria Teresa Voso
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES
Mediterranean Journal of Hematology and Infectious Diseases
Primitive MDS
therapy related MDS
Mutations
Cytogenetics
title DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES
title_full DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES
title_fullStr DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES
title_full_unstemmed DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES
title_short DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES
title_sort de novo and therapy related myelodysplastic syndromes analogies and differences
topic Primitive MDS
therapy related MDS
Mutations
Cytogenetics
url https://www.mjhid.org/index.php/mjhid/article/view/4986
work_keys_str_mv AT profgiuseppeleone denovoandtherapyrelatedmyelodysplasticsyndromesanalogiesanddifferences
AT emilianofabiani denovoandtherapyrelatedmyelodysplasticsyndromesanalogiesanddifferences
AT mariateresavoso denovoandtherapyrelatedmyelodysplasticsyndromesanalogiesanddifferences